IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...

CHICAGO, IL—In experienced hands, compassionate use of the Pascal transcatheter valve repair system in patients with severe high-risk or inoperable tricuspid regurgitation (TR) can be safe and ...

The Irvine, CA-based company said the Pascal repair system demonstrated high procedural success and significant clinical improvements in patients with challenging tricuspid anatomy and severe TR.

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

The latest mitral valve repair and replacement devices were associated with favorable outcomes thus far, investigators reported. The Evoque, Tendyne, and Pascal devices are poised as potential ...

Edwards Lifesciences Corp. has gained a CE mark for its Pascal transcatheter valve repair system to treat tricuspid regurgitation (TR). It was previously approved for mitral regurgitation treatment.

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI Receive the the latest news, research, and presentations from major ...